The appearance of generic version for biosimilar requires statistical methodologies to evaluate biosimilarity between reference products and proposed products. So far, a number of papers are published through rigorous research by researchers; furthermore, the FDA published the guidance paper for industry. The motivation of this paper is not only to make brief summary of demonstrating biosimilarity based on FDA guiadance, but also to introduce a few methodologies on evaluating biosimilarity in one paper.